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The nuclear enzyme, poly(ADP-ribose) polymerase (PARP), is
activated in response to DNAstrand breaks and is strongly implic-
ated in the repair of such lesions (reviewed in de Murcia and
Menissier-de Murcia 1994). It has therefore been proposed that
inhibition of PARP may increase the efficacy of DNA-damaging
anticancer therapy. Indeed, inhibition of PARP has been demon-
strated to increase the cytotoxicity of several anticancer agents
(reviewed in Griffin et al, 1995a). However, in comparison to the
well-defined role of PARP in the repair of methylating agent- and
γ -irradiation-induced DNA damage, the role of PARP in response
to topoisomerase inhibitor-mediated DNA damage has not been
extensively studied. 
Topoisomerases, which catalyse the DNA breakage, unwinding
and religation necessary to relieve torsional strain, are the molec-
ular target of many anticancer agents. In particular, the observation
that topoisomerase I is elevated in some tumours (Kaufmann et al,
1995), has led to increased interest in the use of topoisomerase I
inhibitors in the treatment of cancer. Evidence concerning the role
of PARP in response to treatment with topoisomerase inhibitors is
scant and contradictory. For example, the DNAintercalating topoi-
somerase II inhibitor, doxorubicin, stimulated PARP activity in
L1210 cells in one study (Daugherty et al, 1988) but not in another
(Zwelling et al, 1982). DNAstrand breaks, and hence cytotoxicity,
produced by topoisomerase inhibitors correlates directly with
topoisomerase activity, and in isolated enzyme studies PARP
polyADP-ribosylates topoisomerases I and II, down-regulating
their activity (Ferro and Olivera, 1984; Darby et al, 1985).
Consistent with these observations Mattern et al (1987) demon-
strated potentiation of camptothecin and teniposide cytotoxicity by
the PARP inhibitor, 3-aminobenzamide (3AB), in L1210 cells.
They suggested that topoisomerase I and II activity is normally
down-regulated by polyADP-ribosylation, hence sensitization to
camptothecin and teniposide caused by inhibition of PARP was
due to de-repression of topoisomerase activity rather than a direct
effect of PARP inhibition on DNA repair. However, subsequent
studies in CCRF CEM cells failed to demonstrate potentiation of
etoposide by 3AB (Marks and Fox, 1991). 
As a PARP inhibitor, 3AB lacks potency and specificity (Milam
et al, 1986; Eriksson et al, 1996). It has been shown that potentia-
tion of the activity of cytotoxic drugs by 3AB can be via PARP-
independent mechanisms (Moses et al, 1988a; 1988b; 1990).
Recently, more potent PARP inhibitors have been identified (Suto
et al, 1991; Banasik et al, 1992) and these have been used to clarify
more precisely the role of PARP as a determinant of the activity of
cytotoxic drugs, for example cisplatin (Bernges and Zeller, 1996).
NU1025 (8-hydroxy-2-methyl-quinazolin-4-[3H]one), which is
approximately 50 × more potent than 3AB as a PARP inhibitor
(Griffin et al, 1995b; 1996) has recently been evaluated as a 
resistance modifier. NU1025 can enhance the cytotoxicity of some
classes of DNA-damaging agents (monofunctional DNA-
alkylating agents, γ -irradiation and bleomycin) but not others
(antimetabolites) in L1210 cells (Bowman et al, 1998). In order to
investigate the potential of PARP inhibitors as modulators of the
activity of topoisomerase inhibitors, the effect of NU1025 on
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METHODS
Reagents 
All reagents, unless stated otherwise, were obtained from Sigma
(Sigma-Aldrich Company Ltd, Poole, UK) or BDH Ltd (Poole,
UK). Alcohol dehydrogenase (ADH) and proteinase K were
purchased from Boehringer Mannheim Biochemica (Mannheim,
Germany). [2-14C]-Thymidine (specific activity = 1.96 GBq
mMol− 1) and [methyl-3H]-thymidine (specific activity = 1.85 TBq
mMol− 1) were purchased from Amersham International
(Amersham, UK). Etoposide (VP16) and camptothecin were
dissolved in dry DMSO to give 10 mM stock solutions, and stored
at − 20˚C. NU1025 was prepared as previously described (Griffin
et al, 1995b) and dissolved in DMSO to give 100 mM stock
solutions and stored at − 20˚C. 
Clonogenic cell survival assay 
Exponentially growing L1210 cells (105 cells ml− 1) were exposed
to a range of concentrations, in duplicate, of camptothecin or
etoposide in the presence or absence of 200 µM NU1025 for 16 h
at 37˚C. Camptothecin preferentially kills S-phase cells and cell
replication has been implicated as a determinant of cytotoxicity
(Kaufmann, 1998). Therefore, since the duration of drug exposure
in relation to the cell cycle time is important, cells were exposed
to the drug for > one doubling time (doubling time = 12 h) to
ensure that the drug was present during the S-phase of all replic-
ating cells. All drugs were added in DMSO to give a final concen-
tration of 1% (v/v) DMSO, and untreated controls were also
exposed to 1% (v/v) DMSO. Drug exposure was stopped by
centrifugation and the cells were seeded for colony formation in
0.125% (w/v) agarose (SeaKem; Flowgen Insruments Ltd,
Sittingbourne, UK) in medium. Viable colonies were visualized
by staining with MTT (3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyl-
tetrazolium bromide) solution in PBS (0.5 mg ml− 1) and counted.
The plating efficiencies relative to control for each drug concen-
tration/combination were calculated to give cell survival as a
percentage of control. The plating efficiency for untreated
controls, DMSO controls and cells treated with 200 µM NU1025
were not significantly different from 100% (P > 0.05 Student’s
unpaired t-test). The LC50 and LC90 (concentrations of drug to
give 50% or 90% reduction in cell survival) were calculated using
a point-to-point curve plot using Graphpad PRISM software
(Graphpad Inc, San Diego, CA, USA). 
DNA strand break assay by alkaline elution 
The alkaline elution technique for the quantitative analysis of
DNA single-strand breakage in which fragments of DNA were
separated on the basis of size using polycarbonate filters, which
are neither protein- nor DNA-adsorbent was used as described by
Kohn et al (1981). The alkaline elution assay has been shown
previously to have a sensitivity of 1 DNA lesion/107 nucleotides.
To increase the precision of the assay the samples were co-eluted
with an internal standard consisting of irradiated DNA. Expon-
entially growing L1210 cells labelled with [2− 14C]-thymidine
(14.8 KBq ml− 1) for 24 h followed by 4 h in fresh medium then
treated for 16 h with the drug combinations and concentrations
indicated. They were co-eluted with [methyl-3H]-thymidine (37
KBq ml− 1)-labeled internal standard cells exposed to 3 Gyγ -radia-
tion (using a 137Cs source, Gammacell 1000 elite; Nordion
International Inc, Kanata, Canada). Single-strand break frequency,
calculated as rad equivalents, was determined by comparison with
a calibration curve of elution rate constant (slope determined by
linear regression analysis) vs γ -radiation dose. Under the condi-
tions used here the limit of the sensitivity of the alkaline elution
assay was such that strand-break frequencies of more than 300 rad
equivalents could not be measured with any degree of accuracy. 
PARP activation assay 
L1210 cells were exposed to varying concentrations of campto-
thecin or etoposide for 6 h prior to permeabilization in hypotonic
buffer and cold shock as described previously (Halldorsson et al,
1978). Briefly, cells were suspended in hypotonic buffer (9 mM
HEPES, pH 7.8, 4.5% (v/v) dextran, 4.5 mM MgCl2 and 5 mM
DTT) at 1.5 × 107 ml− 1 on ice for 30 min, then 9 vol of isotonic
buffer (40 mM HEPES, pH 7.8, 130 mM KCl, 4% (v/v) dextran,
2 mM EGTA, 2.3 mM MgCl2, 225 mM sucrose and 2.5 mM DTT)
was added. The reaction was started by adding 300 µl cells to
100 µl 300 µM NAD+ containing [32P]-NAD+ (Amersham, UK),
and terminated by the addition of 2 ml ice-cold 10% (w/v) TCA +
10% (w/v) sodium pyrophosphate. After 30 min on ice the precip-
itated 32P-labelled ADP-ribose polymers were filtered on Whatman
GC/C filters (Whatman International Ltd, Kent, UK), washed five
times with 1% (v/v) TCA, 1% (v/v) sodium pyrophosphate, dried
and counted as described above. 
Apoptosis assay 
A sample of 1–2  × 105 control or drug-treated cells were
centrifuged at 3000 rpm (600 g) for 3 min and resuspended in
20 µl methanol:acetic acid (3:1 v/v) for 2 min. The cells were
stained with 20 µl Hoechest 33258 (8 µg ml− 1 in PBS) and viewed
using UV microscope. A minimum of 600 cells were counted and
apoptotic cells, recognized by condensed chromatin, were
expressed as a percentage of the total number of cells counted. 
RESULTS 
Potentiation of camptothecin and etoposide
cytotoxicity by NU1025 
NU1025 was not cytotoxic per se at 200 µM (% survival for a 16-h
exposure was 100 ± 12%), consistent with the results from the
previous study by Boulton et al (1995). Exposure to the topo-
isomerase I and II inhibitors camptothecin and etoposide for 16 h
induced a concentration-dependent decrease in L1210 cell survival
(Figure 1A and 1B). Camptothecin cytotoxicity was significantly
increased by 200 µM NU1025 (t-test,  P ≤ 0.05), as shown in
Figure 1A; pooled data from three experiments are given in
Table 1. The magnitude of the potentiation was similar at low and
high camptothecin concentrations, with an enhancement factor of
2.6 observed for both LC50 and LC90 values. In contrast there was
no enhancement of etoposide cytotoxicity by NU1025 (Figure 1b,
Table 1). The effects of NU1025 on etoposide cytotoxicity over
a longer exposure period (24 h) were also studied, but again
NU1025 had no effect (data not shown). 
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ADP-ribosylation of topoisomerase II was responsible for the
potentiation of teniposide cytotoxicity by 3AB in L1210 cells. In
the studies performed by these latter authors, cells were exposed to
3-aminobenzamide prior to exposure to teniposide. To investigate
if exposure to a PARP inhibitor prior to etoposide treatment
resulted in increased cytotoxicity, cells were pretreated with
200 µM NU1025 for 16 h, followed by a 2, 4 or 16-h exposure to
etoposide in the presence of NU1025. However, in all cases there
was again no potentiation of etoposide cytotoxicity (data not
shown). 
Effect of NU1025 on DNA strand breaks induced by
camptothecin and etoposide 
DNA strand breakage was measured after a 16-h exposure to the
topoisomerase inhibitors in the presence or absence of 200 µM
NU1025 (Figure 2). Data, expressed as rad equivalents, from three
independent experiments are given in Table 2. No DNA strand
breakage was detected following exposure to 200 µM NU1025
alone (Figure 2A and 2B), consistent with the observation that
exposure of cells to 1 mM NU1025 for 24 h had no effect on DNA
strand-break levels (Boulton et al, 1995). 
108 KJ Bowman et al
British Journal of Cancer (2001) 84(1), 106–112 © 2001 Cancer Research Campaign
1
02 0
Camptothecin (nM) Etoposide (nM)
40 60
10
100 A B
S
u
r
v
i
v
a
l
 
(
%
 
c
o
n
t
r
o
l
)
0.1
0 250 500 750 1000
1.0
10.0
100.0
S
u
r
v
i
v
a
l
 
(
%
 
c
o
n
t
r
o
l
)
Figure 1 Potentiation of (A) camptothecin and (B) etoposide cytotoxicity by NU1025. Cells were exposed to varying concentrations of camptothecin or
etoposide in the presence (open circles) or absence (closed circles) of 200 µM NU1025 for 16 h prior to seeding for colony formation. Data (normalized to
DMSO or 200 µM NU1025 alone controls) are the mean ± standard deviation of triplicate colony counts from each of the cell populations exposed in duplicate 
Table 1 Potentiation of camptothecin and etoposide-induced cytotoxicity by
NU1025 and NU1064. Cells were exposed to camptothecin or etoposide ±
200 µM NU1025 for 16 h. The LC50 and LC90 values were calculated from the
data shown in Figures 1A and 1B. The Enhancement factors give the relative
decrease in LC50 and LC90 values following potentiation by NU1025. Results
are expressed as the mean ± s.d. of three independent experiments. 
Cytotoxic agent Control + NU1025 Enhancement factor
Camptothecin 
LC50(nM) 15 ± 2 6.1 ± 1.7a 2.6 ± 0.4 
LC90(nM) 39 ± 6.5 15 ± 4a 2.6 ± 0.3 
Etoposide 
LC50(nM) 183 ± 64 202 ± 62 no potentiation 
LC90(nM) 763 ± 167 783 ± 177 no potentiation 
aData significantly different in the presence of NU1025 (P = < 0.05) as shown
by a paired, two-tailed, Student’s t-test 
Table 2 DNA damage induced by camptothecin and etoposide ± NU1025.
Cells were exposed to camptothecin or etoposide in the presence or
absence of 200 µM NU1025 for 16 h prior to determination of DNA strand
breakage by alkaline elution. Data are the mean ± s.d. for three independent
experiments of the type shown in Figure 2 
Cytotoxic agent DNA strand-break levels (rad equivalents) 
Without NU1025 + 200 µM NU1025 
Camptothecin 
0 nM 25 ± 7 36 ± 8 
15 nM 33 ± 13 81 ± 27 
40 nM 77 ± 29 172 ± 25 
100 nM 261 ± 11 270 ± 12 
Etoposide 
0 nM 43 ± 32 85 ± 36 
150 nM 104 ± 30 106 ± 39 
400 nM 198 ± 31 190 ± 7 
800 nM 287 ± 19 304 ± 17 Effect of PARP inhibition on topoisomerase cytotoxicity 109
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Although exposure to an LC50 concentration of camptothecin
(15 nM) did not induce significant levels of DNA strand breaks,
compared to control cells, treatment with 40 nM camptothecin
(an LC90 concentration) did produce a significant level of breaks
(Figure 2A, Table 2). Consistent with the cytotoxicity data,
NU1025 increased the DNA strand breakage caused by LC50 and
LC90 concentrations of camptothecin, 2.5-fold and 2.2-fold
respectively. Thus, the magnitude of the increases in camp-
tothecin-induced DNA strand-break levels and cytotoxicity
produced by NU1025 were essentially the same (2.5-fold).
Maximum detectable DNA strand-break levels were produced by
100 nM camptothecin alone (i.e. 250–300 rad equivalents), and
hence potentiation of DNA damage by NU1025 at this concentra-
tion could not be determined. 
Treatment of cells with etoposide induced a concentration-
dependent increase in DNA strand-break levels (Figure 2B and
Table 2), and etoposide induced a greater number of DNA breaks
than camptothecin at equitoxic concentrations. Thus, DNA strand
breaks were detectable following treatment with an LC50 concen-
tration of etoposide (150 nM), and maximum detectable DNA
strand-break levels (250–300 rad equivalents) were achieved at the
LC90 concentration of etoposide (800 nM). Consistent with the
cytotoxicity data, NU1025 did not affect the DNA strand-break
levels compared to those observed following treatment with
etoposide alone. 
Effect of camptothecin and etoposide on whole cell
PARP activity 
The potential of the DNA strand breaks induced by camptothecin
and etoposide to activate PARP was measured directly. Cells were
exposed to varying concentrations of camptothecin or etoposide
for 6 h, prior to permeabilization and analysis of PARP activity.
Since the LC90 concentration of camptothecin (40 nM) only
induced a low level of strand breaks (77 rad equivalents), the
higher camptothecin concentrations of 120 nM (which resulted in
approximately 1% cell survival) was also used. Etoposide induced
substantial DNA strand breakage at the LC90 concentration, and
hence 1 µM etoposide was used in these studies. Previous reports
of PARP activation (as determined by NAD+ depletion) following
etoposide treatment have used the much higher concentrations
of 17 µM (Tanizawa et al, 1989), which would be equivalent to
approximately 20 × the IC90 concentration for L1210 cells. To
allow comparison with these published data, the effects of 17 µM
etoposide and an equivalent supralethal concentration of campto-
thecin (1 µM) on PARP activity were compared. Camptothecin at
both 120 nM and 1 µM caused significant activation of PARP,
whereas similarly cytotoxic concentrations of etoposide (1 µM and
17 µM) had no effect on PARP activity (Figure 3). 
Induction of apoptosis by camptothecin and etoposide 
It has been suggested that secondary fragmentation of DNAduring
apoptosis may induce PARP (Negri et al, 1993). To investigate if
apoptotic DNA cleavage was responsible for the observed effects
of camptothecin and etoposide on PARP activity, morpho-
logical examination of Hoechst 33258-stained cells was con-
ducted. Apoptotic cells were identified as those with condensed
chromatin, and levels of apoptotic cells were approximately 1% in
control L1210 cell cultures. Exposure to 120 nM camptothecin for
16 h only induced apoptotic nuclear morphology in 8% of cells;
however, 43% of cells were apoptotic following 16 h exposure to
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Figure 2 Effect of NU1025 on DNA damage by (A) camptothecin and (B) etoposide. Cells were exposed to varying concentrations of camptothecin or
etoposide in the presence (open symbols) or absence (closed symbols) of 200 µM NU1025 for 16 h prior to determination of DNA strand breakage by
alkaline elution. Data are: control = circles, or (A) plus camptothecin; 15 nM = triangles; 40 nM = squares; 100 nM = diamonds and (B) plus etoposide;
150 nM = triangles; 400 nM = squares; 800 nM = diamonds. Representative elution profiles from duplicate samples are shown 110 KJ Bowman et al
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1 µM camptothecin. Similarly, following exposure to IC90 concen-
tration of etoposide for 16 h only 3% of the cells were apoptotic
whereas exposure to 17 µM VP16 induced apoptosis in 37% of
cells. 
From a comparison of the PARP activation and apoptosis data it
would appear that in camptothecin-treated cells PARP activation
results from the primary DNA fragmentation induced by the drug
at LC90 concentrations at early time-points. In contrast to the
effects of camptothecin, primary DNA fragmentation induced by
cytotoxic etoposide concentrations at early time-points does not
appear to stimulate PARP activity. 
DISCUSSION 
We report here an investigation of the role of PARP in topo-
isomerase inhibitor-mediated cytotoxicity using the novel PARP
inhibitor NU1025. Using identical drug-exposure conditions
NU1025 increased camptothecin-induced DNA strand breakage
and cytotoxicity by a similar amount (2.2–2.6-fold), strongly
suggesting that the increase in cytotoxicity was due to increased
DNA strand-break levels. The activation of PARP by camp-
tothecin-induced DNA strand breaks was investigated at concen-
trations at and above the LC90, as lower concentrations produced
too few DNA strand breaks to cause detectable PARP activation.
Concentrations of camptothecin which resulted in ≥ 250 rad equi-
valents DNA strand breakage (120 nM, 1 µM) caused significant
activation of PARP at 6 h. Since the level of apoptosis induced by
120 nM camptothecin was only 8% at 16 h, the effects of camp-
tothecin on DNAstrand breakage and PARPactivation observed at
this concentration were unlikely to be secondary to apoptotic DNA
fragmentation. However, PARP activation following exposure to
1 µM camptothecin may be due to both camptothecin-induced and
apoptosis-associated DNA breaks. Together, these data provide
evidence that PARP is directly activated by camptothecin-induced
DNA damage, and that inhibition of PARP increases the level of
DNAstrand breaks and associated cytotoxicity. 
In contrast to its effect on camptothecin cytotoxicity, NU1025
had no effect on etoposide-mediated cytotoxicity or DNA strand
breakage. Consistent with the lack of an effect of NU1025 on
etoposide-mediated DNA strand breakage and cytotoxicity PARP
activation was not observed following exposure to approximately
LC90 (1 µM) etoposide, despite the observation that significant
levels of DNA strand breakage occurred. Following exposure to a
supralethal (17 µM) concentration of etoposide for 16 h approx-
imately 40% of the cells were found to be apoptotic but no PARP
activation was detected at 6 h (Figure 3). Therefore, either PARPis
not activated following secondary etoposide-induced apoptotic
DNA fragmentation or such fragmentation occurs at a later stage.
From previous studies it would appear that etoposide-induced
PARP activation is dependent not only on the concentration and
schedule of etoposide exposure, but also on the cell type. For
example, etoposide has been found to activate PARP in HL-60,
U939 and HeLa cells but not Molt 4 and CEM cells (Tanizawa et
al, 1989; Kubota et al, 1990; Negri et al, 1993; Bernardi et al,
1995). Together, the failure of NU1025 to enhance etoposide cyto-
toxicity or DNA strand breakage, and the lack of PARP activation
following etoposide treatment, indicate that PARP is not involved
in etoposide cytotoxicity in L1210 cells. 
The differential effect of PARP inhibition on camptothecin and
etoposide cytotoxicity in L1210 cells may be due to differences
in the nature of the DNA strand breaks formed by the two drugs.
Etoposide induces only protein (topoisomerase II)-associated
double- and single-stranded DNA breaks and cross-links. The
associated proteins may prevent PARP binding to the DNA strand
break, and hence PARP activation. In contrast, it has been
proposed that collision between the DNA replication fork
and camptothecin-topoisomerase I complex produces a protein-
associated single-strand break and a non-protein-associated
double-strand break 3' to the complex, (Pommier et al, 1994).
Indeed, DNA double-strand ends have been detected in extracts
from human colon carcinoma cells treated with camptothecin
(Strumberg et al, 1999). Blunt-ended double-strand breaks are
potent activators of PARP (Benjamin and Gill, 1980) and these
lesions may be responsible for the activation of PARP following
camptothecin treatment. 
The potentiation of camptothecin by NU1025 is particularly
interesting as it does not coincide with current theories of PARP
involvement with BER pathways (Dantzer et al, 1999) and further
work is needed to identify the lesion responsible for the activation
of PARP by camptothecin. Little is known about repair of
camptothecin-induced DNA damage, although an enzyme with
3'-specific tyrosyl-DNA phosphodiesterase activity has been
described which may be involved in the repair of topoisomerase
I-DNA complexes (Yang et al, 1996). It is conceivable that the
steps subsequent to topoisomerase I removal by this repair enzyme
could involve some mechanism common to the BER pathway.
Recently it has been proposed that BER is accomplished by a
multiprotein complex consisting of PARP, XRCC1, DNA poly-
merase β and DNA ligase II (Caldecott et al, 1996; Mason et al,
1998). Interestingly, EM9 cells with defective XRCC1 are hyper-
sensitive to camptothecin (Caldecott and Jeggo, 1991) but not
etoposide (Jeggo et al, 1989). BER may be associated with the
repair of replication-independent camptothecin-induced DNA
damage as aphidicolin, which protected wild-type cells, had only a
modest protective effect in camptothecin-treated EM9 cells
(Barrows et al, 1998). Similarly, PARP-deficient V79 cells are
hypersensitive to topoisomerase I inhibitors (Chatterjee et al,
1990) but resistant to etoposide (Chatterjee et al, 1994). Thus it
would appear that deficiencies in one component of the BER
complex, as in EM9 cells, or inhibition of another component,
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Figure 3 PARP activity in whole cells following treatment with camptothecin
and etoposide. Cells were exposed to varying concentrations of
camptothecin or etoposide for 6 h prior to permeabilization and assay for
PARP activity. Data are the mean ± s.d. for quadruplicate samples from each
of the cell populations exposed in duplicate. 0 = control PARP as described in this study, sensitizes cells to camptothecin
but not etoposide, implicating BER in repair of topoisomerase
I-but not topoisomerase II-mediated DNAdamage. 
On the basis of the studies reported here, PARP inhibitors
would appear to be potentially useful as resistance-modifying
agents in combination with topoisomerase I inhibitor anticancer
chemotherapy. Further work in this laboratory using a panel of 12
cell lines demonstrates that potentiation of topoisomerase I
poisons by PARP inhibitors is not a cell line-specific phenom-
enon, in that in all evaluable cells NU1025 increased topotecan
cytotoxicity by 1.2–5.5-fold (Delaney et al, 2000). Further inves-
tigation of the role of PARPin topoisomerase I inhibitor-mediated
cytotoxicity, which may lead to a better understanding of the
mechanism of topoisomerase inhibitor-mediated cytotoxicity, are
warranted. 
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